Publications by authors named "M D Rarick"
Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcinoma.
View Article and Find Full Text PDFPurpose: TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer.
Patients And Methods: Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m(2)), gemcitabine plus TH-302 240 mg/m(2) (G+T240), or gemcitabine plus TH-302 340 mg/m(2) (G+T340).
Article Synopsis
- The study assessed the effectiveness of imetelstat, a telomerase inhibitor, as a switch maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) who had stable disease after initial chemotherapy.
- Out of 116 enrolled patients, those treated with imetelstat showed similar progression-free survival (PFS) compared to the control group, with a slight median survival advantage for imetelstat but not statistically significant.
- An exploratory analysis suggested potential benefits of imetelstat in patients with short telomere length (TL), indicating that TL could be a promising biomarker for treatment response, but further research is needed.